Neurodegenerative Diseases Modeling

Categories: Pesticides

Neurodegenerative diseases modeling is necessary for studying symptoms, signs and curative approaches of most neurodegenerative diseases. Many neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease have been discovered, however, Parkinson’s disease (PD) is the most common neurodegenerative movement disorder identified (Kikuchi et al., 2017).

Parkinson’s disease (PD) occurs as a result of the degeneration of dopaminergic neuronal cells in the substantia nigra pars com¬pacta (SNpc) (Jian-Ming and Hiu-Guang, 2004).

With motor function defects like tremor at rest, rigidity, bradykinesia, and postural instability, Parkinson’s disease has been rated the second most common neurodegenerative disease (Meireles and Massano, 2012).

However, some patients suffering from PD have also exhibited insomnia, autonomic dysfunction, hyposmia, depression, and dementia (Petit et al., 2014). The cause of sporadic PD is unknown, with uncertainty about the role of environmental toxins and genetic factors (William and Serge, 2003). Some neuro-toxic compounds could result in rodents producing symptoms that mimic human PD, hence, the use of toxin-induced models in PD experiments.

These toxin-induced models may help researchers get to the bottom of the etiology of PD and develop curative therapies to manage it.

Many models have been developed and are being used for Parkinson disease research but the common model being used is the toxic- induced model, however, the reasons for a choice of a model for particular research and the pathogenesis of the choice of a typical model is not understood by most researchers, leading to incorrect administration route, delay experimental time, experiment failure and additional cost.

Top Writers
Tutor Janice
Verified writer
4.9 (549)
Expert Writers
Verified writer
4 (256)
Academic Giant
Verified writer
5 (345)
hire verified writer

Therefore, there is a need for studying the developmental process and the shortcoming of each toxic-induce model used to induce Parkinson’s disease, to bring out the understanding of their pathways, shortcomings and educate researchers on the type to select for any given experiment. This review seeks to enlighten readers on the pathogenesis and the shortcoming of these toxics when used as models to induced Parkinson’s disease to aid perfect selection and development of these models for the right research work.

Etiology of Parkinson’s Disease

The major cause of Parkinson’s disease is unknown. However, many studies have deduced some common causes of Parkinson’s disease. The first and most known cause of Parkinson’s disease is environmental factors like water, pesticides, herbicides, farming activities and living activities of man (Tanner and Langston, 1990).

It has been reported that workers exposed to toxins and heavy metals have the highest risk of PD (Caudle, 2015) and the exposure to agricultural chemicals like rotenone and paraquat have harmful effects on the dopaminergic neurons (De Lau and Breteler, 2006). Many cases of PD have been associated with a toxin applied in the environment. The most known toxin that has been reported to cause PD is MPTP (1,2,3,6-methyl-phenyl-tetrahydropyridine), This was strengthened by the fact that there was a high risk for developing PD for people who lived in environments with pesticides related in structure to MPTP (Firestone et al., 2005).

Also, Drug addicts who took MPTP developed a syndrome that strikingly resembled PD, both clinically and pathologically (Langston et al., 1983). Another interesting side of PD etiology is genetic factors. Several genes have been screened and found to be linked with an increased risk of PD, the 16 loci, designated PARK1 to PARK16 and other 11 genes on different chromosomes are associated with a higher risk of PD (Corti et al., 2011).

Mutation of some genes in the brain section can also cause PD by affecting some gene expressions and these can be hereditary or not. A study by Ikebe et al., (1995) sequenced total mitochondrial DNA in five sporadic PD patients and observed different point mutations in a subunit of complex I in each patient. Subsequently, a mutation was detected in the gene that encodes for the protein α-synuclein in a family (Polymeropoulos et al., 1997). In some hereditary forms of PD, mutations in parkin and ubiquitin C, are responsible for the development of rarer hereditary forms of PD (Chung et al., 2004).

N-synuclein is a protein located at the presynaptic terminals and plays an important role in the vesicular release of neurotransmitters, axonal transport, and mechanisms of autophagy (Ben-Gedalya et al., 2009, Koprich et al., 2011). This gene mutation may alter the structure of α-synuclein, making it more prone to self-aggregation and therefore difficult to be destroyed by proteasomes (Polymeropoulos, 1998) and this may result to PD by oxidative damage (Jenner & Olanow, 1998). These findings confirm that a single mutation of α –synuclein can induce PD.

Pathogenisis of Parkinson Disease

The most essential the characteristic feature that helps in the identification and development of suitable therapies of PD is the loss of dopamine neurons in the substantia nigra pars compacta (SNpc) just as reported by Zigmond and Burkes., (2002), that neurologic deficits results when the availability of dopamine falls below the level required for rapid compensation.

Oxidative stress and mitochondria dysfunction is also another tool for PD pathogenesis and development (Aroso et al., 2016). Oxidative stress induces oxidative metabolism of dopamine to yield hydrogen peroxide (H2O2) and other reactive oxygen species (ROS) (Olanow, 1993). Antioxidants such as vitamins E and C have been identified to protect dopaminergic cells against free radicals in the early stages of the PD (Devore et al., 2010).

Rodriguez-Pallares et al., (2012), reported that the activation of mitochondrial ATP sensitive potassium channels enhances angiotensin-induced oxidative damage and promotes dopaminergic neuron degeneration. Also, a selective 30–40% decrease in complex I activity of the mitochondrial respiratory chain was reportedly found in the SNc of PD patients (Schapira et al., 1990). Other examples of PD pathogenesis include iron accumulation (Shengstock et al., 1994) and Lewy bodies (Gibb et al., 1991)

Cite this page

Neurodegenerative Diseases Modeling. (2021, Oct 31). Retrieved from

Neurodegenerative Diseases Modeling
Let’s chat?  We're online 24/7